Anlotinib Not Yet Recruiting Phase 2 Trials for Neoplasms, Lung / Carcinoma NOS / Lung Cancer Small Cell Lung Cancer (SCLC) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03780283Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC